NEFL and amyotrophic lateral sclerosis: Endpoints may differ slightly between groups, with motor function outcomes often prioritized in ALS cohorts and cognitive and behavioral measures emphasized for FTD participants, although shared biomarkers, such as neurofilament light chain (NfL) levels or imaging markers, are increasingly being used to assess treatment response across both conditions [12,13].